INDIANAPOLIS, April 6,  2011 /PRNewswire/ — Roche (SIX:
RO, ROG; OTCQX: RHHBY) announced today that the David H. Koch
Institute for Integrative Cancer Research at MIT will be using the
Roche LightCycler® 480 System, a real-time polymerase
chain reaction (PCR) system for the analysis of gene expression and
genetic variation, in advanced cancer research.

The Koch Institute plans to use the LightCycler 480 System to
support several key areas of research it has identified as being
critical for rapid progress toward controlling cancer, such as
exploring the molecular and cellular basis of metastasis and
engineering the immune system to fight cancer.  The Institute
is affiliated with the Massachusetts Institute of Technology in
Cambridge, Mass.

“Our approach at MIT offers a unique collaboration between
scientists and engineers, which has helped place us at the
forefront of the fight against cancer,” said Robert Urban,
executive director of the Koch Institute. “The LightCycler
instruments will provide the platform to help us take advantage of
the many applications for real-time PCR technology in cancer
research.”

The LightCycler 480 System is a fully integrated, 96-well and
384-well plate-based real-time PCR platform for the qualitative and
quantitative detection of nucleic acids. It can be used in a broad
range of applications in research fields, such as gene expression
studies, discovery and analysis of genetic variation, or array data
validation. More information is available at www.roche-applied-science.com.

About RocheHeadquartered in Basel, Switzerland, Roche is a
leader in research-focused healthcare with combined strengths in
pharmaceuticals and diagnostics. Roche is the world’s largest
biotech company with truly differentiated medicines in oncology,
virology, inflammation, metabolism and CNS. Roche is also the world
leader in in-vitro diagnostics, tissue-

‘/>”/>

SOURCE